Mission From the moment of our founding we knew that we could transform the biopharmaceutical industry. We had the right people, the right science, and the unwavering commitment to bring about a new approach to drug discovery and development that would deliver innovative treatments to patients where no others had proven effective or ever existed.
Ionis is where passionate, driven people come together to help patients in need. Our success is a direct result of our outstanding employees.
Located in the North San Diego County city of Carlsbad, we’re an industry leader in the discovery and development of antisense drugs. Our work environment is challenging, motivating, rewarding, and designed to foster innovation and scientific excellence.
If you have this same commitment to be a force for life and feel that Ionis is right for you, we want to hear from you.
Description Ionis is the leading innovator in RNA-targeted therapeutics and was purposely designed to create a better, more efficient drug discovery platform, establish a new innovation-centered business model, and maximize the value of every medicine we create and get it to the people who need it most as quickly and as efficiently as possible. Today we are a sustainably profitable, multi-product company that is delivering tansformative breakthroughs for patients…again and again.
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
At Ultragenyx, we’re going beyond every day to transform the lives of people living with rare diseases and lead the future of rare disease medicine. We built our team and our company from the ground up to pioneer new medicines and approaches to drug development for rare and ultrarare diseases and overcome the challenges inherent to treating small patient populations and previously untreated conditions. In 15 years, we’ve achieved four approved therapies in five indications, with a robust pipeline of late-stage therapeutic candidates for debilitating conditions. Our approach to development is informed by patient experience and insights, and we share our science and expertise to help move the entire field forward.
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Ionis Pharmaceuticals has an employee rating of 4.0 out of 5 stars, based on 127 company reviews on Glassdoor which indicates that most employees have a good working experience there. The Ionis Pharmaceuticals employee rating is in line with the average (within 1 standard deviation) for employers within the Pharmaceutical & Biotechnology industry (3.5 stars).
Overall, 81% of employees would recommend working at Ionis Pharmaceuticals to a friend. This is based on 126 anonymously submitted reviews on Glassdoor.
55% of job seekers rate their interview experience at Ionis Pharmaceuticals as positive. Candidates give an average difficulty score of 2.9 out of 5 (where 5 is the highest level of difficulty) for their job interview at Ionis Pharmaceuticals.